Is HRT Safe for the Heart? 2026 Safety & Risks Guide

What the Evidence Actually Says About HRT and Heart Health

The short answer is that HRT appears cardiovascularly safe, and possibly beneficial, for most healthy women who start it early. The longer answer requires unpacking two decades of evolving data, beginning with a trial that changed prescribing patterns across an entire generation.

The Women's Health Initiative (WHI), published in 2002, reported that combined conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) increased coronary heart disease (CHD) events. That finding contributed to a sharp drop in HRT prescriptions across the United States in the years that followed. What received far less attention at the time was a subsequent age-stratified reanalysis suggesting the elevated risk was concentrated in women who were further past menopause when they enrolled.

The WHI Reanalysis Changed the Conversation

Rossouw et al. published a 2007 age-stratified analysis in JAMA looking at cardiovascular outcomes by age and years since menopause (1). The direction of the finding was consistent: coronary heart disease risk trended lower in women who started therapy closer to menopause and trended higher in women who started a decade or more after menopause. Specific hazard ratios and the exact age-interaction statistics are cited inconsistently across secondary sources, so any precise figure quoted from this paper should be checked directly against the original text before it goes into a published version of this article.

This reanalysis is the foundation of what clinicians now call the "timing hypothesis" or "window of opportunity."

What "Timing Hypothesis" Means Clinically

The timing hypothesis holds that estrogen may be vasculoprotective on healthy, estrogen-receptive endothelium but may destabilize plaque when applied to arteries that already have advanced atherosclerosis. A 2004 study by Clarkson, using a non-human primate model, found that estrogen given immediately after ovary removal produced a substantial reduction in coronary artery plaque, while the same treatment produced no measurable benefit when started about two years later (2). This is animal-model evidence, not a human outcome trial, and the specific percentage reduction sometimes quoted from this study should be verified before being repeated as a headline statistic. Its real value here is mechanistic: it offers a biological explanation for why timing might matter.

According to The Menopause Society's 2022 position statement, hormone therapy offers favorable benefits relative to risks when used to address hot flashes and night sweats or to prevent bone loss and fractures in women under 60 or in their first decade after menopause, provided they have no medical reasons to avoid it (3). This represents the professional consensus of an expert organization synthesizing available research; however, it does not confirm that this article itself has received medical review.

How Route of Delivery Changes Cardiovascular Risk

Route matters as much as timing. Not all estrogen delivery systems carry the same clot and stroke profile.

Oral Estrogen and VTE Risk

Oral estrogen undergoes first-pass hepatic metabolism, which raises coagulation factor synthesis (particularly factor VII and fibrinogen) and lowers protein S. Cohort data referenced under the E3N study name have reported that oral estrogen users have a meaningfully higher venous thromboembolism (VTE) risk than never-users, while transdermal users have not shown a statistically significant increase (4). Note for the editor: the PMID linked here appears, by its numbering, to correspond to an earlier publication than the 2007 Circulation paper it is commonly cited as; the exact source and its precise relative-risk figures should be confirmed before this citation is finalized.

A 2019 BMJ analysis by Vinogradova et al., using a large primary-care database, reported a similar pattern: oral estradiol and oral conjugated equine estrogen were associated with an increased risk of VTE, while transdermal estradiol was not (5). The exact odds ratios vary by formulation and dose in the original paper and should be quoted directly from the source rather than restated as a single pair of numbers.

Transdermal Estrogen and Stroke Risk

Standard-dose oral estrogen (such as 0.625 mg CEE or 2 mg oral estradiol) is associated with an increase in ischemic stroke risk. Low-dose transdermal estradiol (roughly 50 mcg or below) has not shown the same increase in most of the observational literature.

The ESTHER study (a French case-control study of hormone therapy and thrombotic risk) reported a lower stroke odds ratio for transdermal estrogen than for oral estrogen (6). The exact odds ratios and confidence intervals should be pulled directly from the paper before publication rather than restated from memory.

Why This Matters for Prescribing Decisions

Women with additional VTE risk factors (a known clotting disorder, obesity, or a prior superficial thrombosis) are generally offered transdermal rather than oral estrogen as the default, consistent with guidance from the North American Menopause Society and the British Menopause Society.

The Progestogen Problem: Progesterone vs. Synthetic Progestins

Women with an intact uterus need a progestogen to protect the endometrium from unopposed estrogen. The cardiovascular profile of that progestogen is not neutral.

MPA vs. Micronized Progesterone

Medroxyprogesterone acetate (MPA, sold as Provera) was the progestin used in the WHI. It has some glucocorticoid and androgenic activity that may partly explain the cardiovascular signal seen in the combined-therapy arm of that trial. Micronized progesterone (Prometrium, typically 100-200 mg oral or vaginal) is biochemically identical to endogenous progesterone and does not share those receptor cross-effects.

Cohort data have suggested that combining transdermal estrogen with micronized progesterone carries a lower VTE risk than combining oral estrogen with MPA (4), though, as noted above, the specific source behind this citation needs verification, so the exact magnitude of that difference should not be quoted as a precise number until confirmed.

The KEEPS trial (Kronos Early Estrogen Prevention Study, roughly 700 recently menopausal women followed for about 4 years) found no meaningful difference between low-dose oral CEE and transdermal estradiol versus placebo in coronary artery calcium progression. The trial enrolled recently menopausal women and used micronized progesterone as the progestogen across the active arms (7).

Dydrogesterone as an Alternative

Dydrogesterone (Duphaston) is used extensively in Europe, though it is not widely available in the United States. Observational data, including work from French cohorts, have suggested a more favorable breast cancer risk profile for dydrogesterone-containing regimens than for MPA-containing regimens. The citation available in the current source set for this section is a systematic review of micronized progesterone and breast cancer risk, not a dydrogesterone-specific study (8); it does not directly support a dydrogesterone-specific claim, and a dydrogesterone-specific reference should be added before this section is published. Cardiovascular event data specific to dydrogesterone are limited and would need separate verification.

The DOPS Trial: RCT Evidence for Early HRT and Cardiovascular Outcomes

The Danish Osteoporosis Prevention Study (DOPS) is the randomized controlled trial most directly relevant to the timing hypothesis.

Trial Design and Results

DOPS randomized just over 1,000 recently menopausal women (within about 6 to 24 months of their last period) to triphasic oral estradiol-norethisterone acetate or no treatment, with a 10-year intervention period and 6 additional years of follow-up. After 16 years total, the HRT group showed a reduction in the composite endpoint of mortality, myocardial infarction, and heart failure, with a hazard ratio of 0.48 (95% CI 0.26-0.87) (9).

This is among the larger and longer randomized datasets supporting a cardiovascular benefit from early-initiated HRT, though it is a single trial rather than a replicated body of RCT evidence.

Limitations to Keep in Mind

DOPS was not blinded after year 10 (participants could choose to continue or stop treatment), and it used an oral norethisterone-containing formulation rather than MPA or micronized progesterone, which limits how directly it can be compared with WHI. The directional finding is nonetheless consistent with the broader timing hypothesis: early initiation in healthy, recently menopausal women did not increase cardiovascular events in this trial and may have reduced them.

Women Who Should Avoid HRT or Use Extreme Caution

Not every woman is a candidate. The cardiovascular safety data described above applies primarily to healthy women who start HRT near menopause. Several subgroups face genuinely elevated risk.

Established Cardiovascular Disease

Women with a prior heart attack, unstable angina, or known coronary artery disease have arteries that may already carry vulnerable plaque. Applying estrogen to those vessels may destabilize plaque rather than protect it, consistent with the WHI findings in older participants. The Heart and Estrogen/Progestin Replacement Study (HERS) followed women with existing coronary heart disease and found no reduction in recurrent CHD events with combined HRT, along with a trend toward early harm in the first year (10). HRT is not indicated for secondary cardiovascular prevention.

Prior VTE or Known Thrombophilia

Oral estrogen meaningfully raises VTE risk. Women with a personal history of DVT, pulmonary embolism, or a confirmed thrombophilia (such as factor V Leiden or antiphospholipid syndrome) generally should not use oral estrogen. Transdermal estrogen may be considered with specialist input, with risk and benefit weighed individually.

Uncontrolled Hypertension

Systolic blood pressure above roughly 160 mmHg is treated as a contraindication to standard-dose estrogen therapy in most guidelines. Blood pressure should generally be controlled to below 140/90 mmHg before starting HRT.

More Than 10 Years Post-Menopause Without Prior HRT Use

Starting HRT for the first time more than 10 years after menopause falls outside the window most strongly supported by the timing hypothesis. If vasomotor symptoms are still significant and quality of life is affected, a specialist risk-benefit discussion is warranted, but the cardiovascular calculus is less favorable and less studied in this group.

A Cardiovascular Decision Framework for Starting or Continuing HRT

The clinical question is never "is HRT safe in the abstract," but "is HRT safe for this specific woman, starting at this age, on this regimen." The table below summarizes the handful of facts that actually change the recommendation, along with the exceptions and the next step.

Monitoring After Starting HRT

Blood pressure is commonly rechecked around 3 months after starting. Fasting lipids at around 6 months are reasonable for women with borderline baseline LDL, since oral estrogen can raise triglycerides. An annual cardiovascular symptom review is good practice.

Women who develop new hypertension, migraine with aura, or unexplained leg swelling or pain after starting HRT should be evaluated promptly, with HRT held pending assessment.

Absolute Versus Relative Risk: Putting the Numbers in Context

Relative risk figures dominate headlines, but for an individual patient, the direction and rough size of the absolute change matters more than a precise decimal.

Based on the studies described above, the general pattern for healthy women in their 50s starting HRT within 10 years of menopause looks roughly like this:

This is a directional summary, not a set of confirmed absolute rates. The specific per-10,000-woman-year figures that are sometimes quoted for these outcomes vary across studies and should be pulled directly from the cited papers, with input from a reviewing clinician, before any exact number is published. Individual risk also depends on baseline blood pressure, BMI, smoking status, and family history, none of which a general risk table can capture.

Current Guideline Positions in 2026

Guidelines have converged considerably since the initial WHI publication in 2002.

NAMS 2022

The North American Menopause Society's 2022 position statement affirms hormone therapy as an effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause, and notes it can help prevent bone loss and fracture. The statement describes a favorable benefit-risk ratio for women younger than 60 or within 10 years of menopause onset who have no contraindications (3). It does not list cardiovascular disease itself as an automatic contraindication for women who start early and otherwise qualify.

British Menopause Society 2023

The BMS 2023 guidance describes transdermal estrogen combined with micronized progesterone or dydrogesterone as the preferred regimen for women with elevated thrombotic risk, and endorses the timing hypothesis as a basis for initiation decisions. The guidance also notes that HRT does not need to be stopped at age 60 if it was started appropriately and the woman remains symptomatic and benefiting from treatment.

ESC / AHA Position

Both European and American cardiology bodies generally state that HRT should not be used as a primary or secondary cardiovascular prevention strategy, while acknowledging that appropriately timed, symptom-driven treatment in younger postmenopausal women does not appear to add meaningful cardiovascular risk, and that transdermal delivery is preferred when VTE risk is a concern. A specific European Society of Cardiology citation was available in source material for this topic, but its title concerns cardiovascular disease during pregnancy rather than menopausal hormone therapy (11); it should not be relied on to support this paragraph, and a correct ESC menopause-specific reference should be added before publication.

A Note on Testosterone and Cardiovascular Risk in Women

Low-dose testosterone is increasingly prescribed alongside HRT for libido and energy in perimenopausal and postmenopausal women. Current evidence, including the 2019 Global Consensus Position Statement on testosterone therapy for women, does not describe an increased cardiovascular risk signal at physiological female-range doses, though the statement also notes that long-term randomized data beyond about 2 years remain limited (12).

Supraphysiological dosing, which can occur with compounded testosterone preparations dosed at male-equivalent levels, is associated with LDL increases, HDL decreases, and elevated hematocrit. Those effects carry real cardiovascular implications. Standard female dosing has not shown the same pattern.